Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

The Role of Tumor Suppressor DLC-1: Far From Clear

Author(s): Xu Liu, Yao-Jie Pan, Jun-Nian Zheng* and Dong-Sheng Pei*

Volume 17, Issue 7, 2017

Page: [896 - 901] Pages: 6

DOI: 10.2174/1871520616666160907142754

Price: $65


Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and was often found to be deleted in hepatocellular carcinoma (HCC).

Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria.

Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found to play a pivotal role in regulating DLC-1.

Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms linked to DLC-1 remain undefined.

Keywords: DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy